T790M mutation positive 2nd line STandard of cAre Registry

Trial Identifier: D5160R00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: June 2015
Primary Completion Date: June 2018
Study Completion Date: June 2018
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Guangzhou, China
China Jiangsu, China
China Jilin, China
China Shanghai, China
China Shanghai Ruijin Hospital, China
China Sichuan Cancer Hospital, China
China Xian, China
France Boulogne Billancourt, France
France Bretagne, France
France La Chaussee-Saint-Victor, France
France Lille, France
France Pontoise, France
France Rhone-Alpes, France
France SAINT QUENTIN, France
Germany Esslingen, Germany
Italy Catania, Italy
Italy Ferrara, Italy
Italy Messina, Italy
Italy Modena, Italy
Italy Napoli, Italy
Italy Padova, Italy
Italy Parma, Italy
Italy Perugia, Italy
Italy Rome, Italy
Italy Torino, Italy
NL Groningen, NL
Russia Barnaul, Russia
Russia Saint Petersburg, Russia
Russia Saint- Petersburg, Russia
Spain Alicante, Spain
Spain Badalona, Spain
Spain Barcelona, Spain
Spain La Coruna, Spain
Spain Leon, Spain
Spain Lugo, Spain
Spain Madrid, Spain
Spain Ourense, Spain
Spain Pamplona, Spain
Spain Santander, Spain
Spain Sevilla, Spain
Spain Valencia, Spain
Spain Vizcaya, Spain
Taiwan LinKou, Taiwan
Taiwan Taichung, Taiwan
Taiwan Taipei, Taiwan
USA, Kentucky Kentucky, USA
USA, Maryland Maryland, USA
USA, Pennsylvania Langhorne, Pennsylvania, USA